Table 16. Open in new tab MIC and...

						Susceptibility
AMC^a,b	81	0.25	1	≤0.015	2	100.0 (98.8)^c	0	0 (1.2)^c	100.0 (100.0)	100.0 (97.5)^c	0	0 (2.5)^c
Ampicillin	81	0.12	2	≤0.015	32	87.7	4.9	7.4	NA	87.7	0	12.3
Azithromycin	81	1	2	0.12	16	98.8	0	1.2	NA	NA	NA	NA
Cefaclor^b	81	2	4	≤0.015	16	98.8 (97.5)^c	1.2 (1.2)^c	0 (1.2)^c	21.0	NA	NA	NA
Cefepime	81	0.12	0.25	≤0.015	0.5	100.0	0	0	NA	93.8	0	6.2
Cefixime	81	0.03	0.03	≤0.015	0.25	100.0	0	0	100.0	98.8	0	1.2
Cefpodoxime	81	0.06	0.25	≤0.015	0.5	100.0	0	0	100.0	92.6	7.4	0
Ceftriaxone	81	0.004	0.015	≤0.002	0.03	100.0	0	0	100.0	100.0	0	0
Cefuroxime^b	81	0.5	2	≤0.015	4	100.0 (98.8)^c	0	0 (1.2)^c	86.4	17.3 (17.3)^c	69.1 (66.7)^c	13.6 (16.0)^c
Ciprofloxacin	81	0.008	0.5	≤0.002	4	93.8	0	6.2	93.8	92.6	0	7.4
Clarithromycin	81	8	16	0.5	>256	90.1	8.7	1.2	NA	NA	NA	NA
Levofloxacin	81	0.008	0.25	≤0.002	2	100.0	0	0	100.0	98.8	0	1.2
Moxifloxacin	81	0.015	0.25	≤0.002	1	100.0	0	0	100.0	98.8	0	1.2

Susceptibility

MIC (mg/L)

CLSI

PK/PD

EUCAST

Antimicrobial

50%

90%

min

max

AMC^a,b

0.25

≤0.015

100.0 (98.8)^c

0 (1.2)^c

100.0 (100.0)

100.0 (97.5)^c

0 (2.5)^c

Ampicillin

0.12

≤0.015

87.7

4.9

7.4

87.7

12.3

Azithromycin

0.12

98.8

1.2

Cefaclor^b

≤0.015

98.8 (97.5)^c

1.2 (1.2)^c

0 (1.2)^c

21.0

Cefepime

0.12

0.25

≤0.015

0.5

100.0

93.8

6.2

Cefixime

0.03

≤0.015

0.25

100.0

98.8

1.2

Cefpodoxime

0.06

0.25

≤0.015

0.5

100.0

92.6

7.4

Ceftriaxone

0.004

0.015

≤0.002

0.03

100.0

Cefuroxime^b

0.5

≤0.015

100.0 (98.8)^c

0 (1.2)^c

86.4

17.3 (17.3)^c

69.1 (66.7)^c

13.6 (16.0)^c

Ciprofloxacin

0.008

0.5

≤0.002

93.8

6.2

93.8

92.6

7.4

Clarithromycin

0.5

>256

90.1

8.7

1.2

Levofloxacin

0.008

0.25

≤0.002

100.0

98.8

1.2

Moxifloxacin

0.015

0.25

≤0.002

100.0

98.8

1.2

						Susceptibility
AMC^a,b	81	0.25	1	≤0.015	2	100.0 (98.8)^c	0	0 (1.2)^c	100.0 (100.0)	100.0 (97.5)^c	0	0 (2.5)^c
Ampicillin	81	0.12	2	≤0.015	32	87.7	4.9	7.4	NA	87.7	0	12.3
Azithromycin	81	1	2	0.12	16	98.8	0	1.2	NA	NA	NA	NA
Cefaclor^b	81	2	4	≤0.015	16	98.8 (97.5)^c	1.2 (1.2)^c	0 (1.2)^c	21.0	NA	NA	NA
Cefepime	81	0.12	0.25	≤0.015	0.5	100.0	0	0	NA	93.8	0	6.2
Cefixime	81	0.03	0.03	≤0.015	0.25	100.0	0	0	100.0	98.8	0	1.2
Cefpodoxime	81	0.06	0.25	≤0.015	0.5	100.0	0	0	100.0	92.6	7.4	0
Ceftriaxone	81	0.004	0.015	≤0.002	0.03	100.0	0	0	100.0	100.0	0	0
Cefuroxime^b	81	0.5	2	≤0.015	4	100.0 (98.8)^c	0	0 (1.2)^c	86.4	17.3 (17.3)^c	69.1 (66.7)^c	13.6 (16.0)^c
Ciprofloxacin	81	0.008	0.5	≤0.002	4	93.8	0	6.2	93.8	92.6	0	7.4
Clarithromycin	81	8	16	0.5	>256	90.1	8.7	1.2	NA	NA	NA	NA
Levofloxacin	81	0.008	0.25	≤0.002	2	100.0	0	0	100.0	98.8	0	1.2
Moxifloxacin	81	0.015	0.25	≤0.002	1	100.0	0	0	100.0	98.8	0	1.2

Table 16.

Open in new tab

MIC and susceptibility results for all H. influenzae isolates from the UAE

						Susceptibility
		MIC (mg/L)				CLSI			PK/PD	EUCAST
Antimicrobial	n	50%	90%	min	max	%S	%I	%R	%S	%S	%I	%R
AMC^a,b	81	0.25	1	≤0.015	2	100.0 (98.8)^c	0	0 (1.2)^c	100.0 (100.0)	100.0 (97.5)^c	0	0 (2.5)^c
Ampicillin	81	0.12	2	≤0.015	32	87.7	4.9	7.4	NA	87.7	0	12.3
Azithromycin	81	1	2	0.12	16	98.8	0	1.2	NA	NA	NA	NA
Cefaclor^b	81	2	4	≤0.015	16	98.8 (97.5)^c	1.2 (1.2)^c	0 (1.2)^c	21.0	NA	NA	NA
Cefepime	81	0.12	0.25	≤0.015	0.5	100.0	0	0	NA	93.8	0	6.2
Cefixime	81	0.03	0.03	≤0.015	0.25	100.0	0	0	100.0	98.8	0	1.2
Cefpodoxime	81	0.06	0.25	≤0.015	0.5	100.0	0	0	100.0	92.6	7.4	0
Ceftriaxone	81	0.004	0.015	≤0.002	0.03	100.0	0	0	100.0	100.0	0	0
Cefuroxime^b	81	0.5	2	≤0.015	4	100.0 (98.8)^c	0	0 (1.2)^c	86.4	17.3 (17.3)^c	69.1 (66.7)^c	13.6 (16.0)^c
Ciprofloxacin	81	0.008	0.5	≤0.002	4	93.8	0	6.2	93.8	92.6	0	7.4
Clarithromycin	81	8	16	0.5	>256	90.1	8.7	1.2	NA	NA	NA	NA
Levofloxacin	81	0.008	0.25	≤0.002	2	100.0	0	0	100.0	98.8	0	1.2
Moxifloxacin	81	0.015	0.25	≤0.002	1	100.0	0	0	100.0	98.8	0	1.2

						Susceptibility
		MIC (mg/L)				CLSI			PK/PD	EUCAST
Antimicrobial	n	50%	90%	min	max	%S	%I	%R	%S	%S	%I	%R
AMC^a,b	81	0.25	1	≤0.015	2	100.0 (98.8)^c	0	0 (1.2)^c	100.0 (100.0)	100.0 (97.5)^c	0	0 (2.5)^c
Ampicillin	81	0.12	2	≤0.015	32	87.7	4.9	7.4	NA	87.7	0	12.3
Azithromycin	81	1	2	0.12	16	98.8	0	1.2	NA	NA	NA	NA
Cefaclor^b	81	2	4	≤0.015	16	98.8 (97.5)^c	1.2 (1.2)^c	0 (1.2)^c	21.0	NA	NA	NA
Cefepime	81	0.12	0.25	≤0.015	0.5	100.0	0	0	NA	93.8	0	6.2
Cefixime	81	0.03	0.03	≤0.015	0.25	100.0	0	0	100.0	98.8	0	1.2
Cefpodoxime	81	0.06	0.25	≤0.015	0.5	100.0	0	0	100.0	92.6	7.4	0
Ceftriaxone	81	0.004	0.015	≤0.002	0.03	100.0	0	0	100.0	100.0	0	0
Cefuroxime^b	81	0.5	2	≤0.015	4	100.0 (98.8)^c	0	0 (1.2)^c	86.4	17.3 (17.3)^c	69.1 (66.7)^c	13.6 (16.0)^c
Ciprofloxacin	81	0.008	0.5	≤0.002	4	93.8	0	6.2	93.8	92.6	0	7.4
Clarithromycin	81	8	16	0.5	>256	90.1	8.7	1.2	NA	NA	NA	NA
Levofloxacin	81	0.008	0.25	≤0.002	2	100.0	0	0	100.0	98.8	0	1.2
Moxifloxacin	81	0.015	0.25	≤0.002	1	100.0	0	0	100.0	98.8	0	1.2

min, minimum; max, maximum; AMC, amoxicillin/clavulanic acid; S, susceptible; I, intermediate; R, resistant; NA, no breakpoint data available (NA for azithromycin and clarithromycin by EUCAST because Etest^® breakpoints in CO₂ not available).

^aAmoxicillin/clavulanic acid PK/PD susceptibility at high dose is shown in parentheses.

^bIn clinical settings, isolates of BLNAR are considered resistant to amoxicillin/clavulanic acid, cefaclor and cefuroxime (see main text).

^cSusceptibility to amoxicillin/clavulanic acid, cefaclor and cefuroxime (data in parentheses) due to corrections according to BLNAR (see main text).

This Feature Is Available To Subscribers Only